Brooks Automation, Inc. — Fiscal 2013 Form 10-K Summary
Reporting period: Fiscal year ended September 30, 2013, including fourth-quarter results. The supplied filing identifies the registrant as Brooks Automation, Inc. (NASDAQ: BRKS), not Azenta, Inc.; investors should verify the requested company name against the filing.
Business Context
Brooks provided automation, vacuum, instrumentation, service, and life-science sample-management solutions. Fiscal 2013 revenue was generated across Brooks Product Solutions, Brooks Global Services, and Brooks Life Science Systems. Semiconductor capital equipment represented 53% of revenue, down from 54% in fiscal 2012 and 65% in fiscal 2011. Life sciences represented 10% of revenue.
The company acquired Crossing Automation in October 2012 for approximately $59.0 million and Matrical assets in August 2013 for approximately $9.3 million. It continued restructuring following the Crossing acquisition and divested its contract-manufacturing business in 2011.
Financial Performance and Liquidity
| Metric | FY2013 | FY2012 | Change |
|---|---|---|---|
| Revenue | $451.0 million | $519.5 million | Down 13% |
| Gross profit | $146.0 million | $173.5 million | Down 16% |
| Gross margin | 32.4% | 33.4% | Down 1.0 percentage point |
| Operating income (loss) | $(9.0) million | $9.6 million | Declined to a loss |
| Net income (loss) attributable to Brooks | $(2.2) million | $136.8 million | Prior year included major tax benefit |
| Diluted EPS | $(0.03) | $2.08 | Declined to a loss |
| Cash flow from operations | $54.4 million | $36.0 million | Increased |
| Capital expenditures | $3.6 million | $8.7 million | Decreased |
Fourth-quarter revenue was $118.2 million, gross profit was $40.5 million, and net income attributable to Brooks was $6.0 million, or $0.09 diluted EPS. Full-year R&D expense was $49.0 million and SG&A expense was $99.5 million.
At September 30, 2013, cash and cash equivalents were $83.0 million, and total marketable securities were $90.4 million, for approximately $173.4 million of cash, cash equivalents, and marketable securities. Working capital was $237.6 million. The filing does not identify material funded debt; total liabilities were $104.1 million, including $7.0 million of long-term tax liabilities and $0.8 million of long-term pension liabilities.
Material Changes Versus the Prior Comparable Period
- Revenue declined $68.5 million, primarily because of weaker semiconductor capital-equipment demand. Product Solutions revenue decreased 17% to $317.9 million.
- Crossing contributed approximately $41.5 million of revenue but also incurred a $2.6 million after-tax net loss, including purchase-accounting effects and amortization.
- Life Science Systems revenue declined 18% to $43.3 million because customers delayed purchasing decisions; the segment reported a $12.4 million operating loss.
- Gross margin fell to 32.4%, affected by lower production and fixed-cost absorption, $2.7 million of purchase-accounting inventory charges related to Crossing, and approximately $2.0 million of Celigo-related impairment and inventory charges.
- Operating expenses included $6.5 million of restructuring charges, primarily related to approximately 200 eliminated positions, Crossing integration, facility consolidation, and outsourcing Polycold manufacturing.
- Fiscal 2012 net income benefited from a $121.8 million deferred tax benefit from reducing the valuation allowance on deferred tax assets. The fiscal 2013 tax benefit was only $2.2 million.
- Goodwill increased to $122.0 million from $88.4 million, principally from the Crossing and Matrical acquisitions. No goodwill impairment was recorded, although the Life Science Systems reporting unit had only a 10% excess of estimated fair value over carrying value.
- Backlog increased to $107.2 million from $81.1 million, but orders may be canceled or rescheduled and backlog is not a reliable indicator of future revenue.
Outlook, Risks, Contingencies, and Unusual Items
Management reported indications of improved semiconductor-equipment demand and expected fiscal 2014 revenue to improve compared with fiscal 2013. The filing provides no quantified revenue, earnings, or margin guidance.
- The business remains exposed to semiconductor-industry cyclicality, rapid technology changes, competitive pricing pressure, customer concentration, and international currency and operating risks.
- The ten largest customers represented approximately 39% of fiscal 2013 revenue, and Applied Materials represented 11%.
- Life Science Systems depends on improved performance and successful introduction and market acceptance of new products; failure to achieve these assumptions could result in goodwill or intangible-asset impairment.
- Contractual obligations totaled $89.8 million, including $69.1 million of purchase commitments and $19.6 million of operating leases. Outstanding letters of credit totaled $5.7 million.
- Unrecognized tax benefits and related interest totaled $6.9 million, with uncertain settlement timing.
- The company had approximately $242.0 million of federal, $122.2 million of state, and $37.3 million of foreign net operating-loss carryforwards, plus approximately $24.0 million of federal and state R&D tax-credit carryforwards.
- Legal proceedings arose in the ordinary course of business; management did not expect them to have a material adverse effect, while acknowledging that outcomes are uncertain.
- The board declared a subsequent quarterly dividend of $0.08 per share payable December 27, 2013.
Important Facts for Investors to Verify
- Confirm whether the filing should be attributed to Brooks Automation or Azenta, Inc.; the supplied document is a 2013 Brooks Automation 10-K.
- Separate recurring operating performance from the unusual $121.8 million deferred-tax benefit recognized in fiscal 2012.
- Assess whether semiconductor demand actually improved in fiscal 2014 and whether the higher backlog converted into revenue.
- Monitor Life Science Systems profitability and the limited 10% goodwill valuation cushion.
- Evaluate the cash cost and execution risk of restructuring, Polycold outsourcing, and Crossing integration.
- Review customer concentration, purchase commitments, tax exposures, and the sustainability of quarterly dividends during semiconductor downturns.